Joyce Reyes - 10 Mar 2023 Form 4/A - Amendment Insider Report for Histogen Inc.

Reporting relationship: Officer
Issuer ticker: N/A
Reported as of: 10 Mar 2023
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 28 Apr 2023, 18:56:26 UTC
Original report date: 14 Mar 2023
Prior SEC filing: 03 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Susan A. Knudson as attorney-in-fact for Joyce Reyes

Key filing fact

Joyce Reyes filed Form 4/A - Amendment for Histogen Inc. on 28 Apr 2023.

Key facts

This page summarizes Joyce Reyes's Form 4/A - Amendment filing for Histogen Inc..
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 28 Apr 2023, 18:56.

Change

Previous filing in this sequence was filed on 03 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HSTO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +47,417
Change %
Price: $0.000000
Shares after: 47,417
Date: 10 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,417
Exercise price: $0.9500
Footnotes: F1

HSTO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +16,659
Change %
Price: $0.000000
Shares after: 16,659
Date: 10 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,659
Exercise price: $0.9500
Footnotes: F1, F2

HSTO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -1,200
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 10 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,200
Exercise price: $4.80
Footnotes: F3, F4, F5

HSTO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -4,452
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 10 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,452
Exercise price: $4.80
Footnotes: F3, F4, F6

HSTO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -7,833
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 10 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,833
Exercise price: $3.20
Footnotes: F3, F4, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

1/4 of the shares subject to the option vest one year after the date of grant, on 3/10/2024, and the remaining 1/36 of the shares vest on a monthly basis thereafter.

Footnote F2

The shares subject to this option are subject to forfeiture in the event that the shares available pursuant to the Plan are not increased prior to the one-year anniversary and vesting of the award by an amount required to be available for issuance for all outstanding stock awards containing this forfeiture condition.

Footnote F3

Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share.

Footnote F4

On March 10, 2023, the Issuer and the Reporting Person agreed to cancel the stock option award.

Footnote F5

1/4 of the shares subject to the option vested on 9/15/2022 and the remaining 1/36 of the shares vest on a monthly basis thereafter.

Footnote F6

1/4 of the shares subject to the option vested on 11/8/2022 and the remaining 1/36 of the shares vest on a monthly basis thereafter.

Footnote F7

1/4 of the shares subject to the option vest one year after the date of grant, on 6/1/2023, and the remaining 1/36 of the shares vest on a monthly basis thereafter.

SEC remarks

Senior Vice President of Regulatory, Quality, Clinical Operations, and Technical Operations This Form 4/A amends the Form 4 filing made on behalf of the Reporting Person on March 14, 2023. The Form 4, as originally filed, inadvertently omitted the cancelled stock option grant of 4,452 shares.